MEMO

TO: Prevention Partnership Providers and Local Public Health Units

FROM: Molly Howell, MPH
Immunization Program Manager

RE: MENHIBRIX® Availability

DATE: December 17, 2013

MENHIBRIX® (Hib-MenCY-TT) is a combination vaccine that protects against meningococcal groups C and Y and Haemophilus influenzae type B (Hib). **Starting December 17, 2013, MENHIBRIX® will be available for order from the North Dakota Department of Health.** Not every provider will need to keep MENHIBRIX® on hand, as it is recommended only for severely immunocompromised infants. Providers may place orders in single-dose increments in the North Dakota Immunization Information System (NDIIS). MENHIBRIX® may be ordered from the NDDoH for Vaccines For Children (VFC) eligible children and for insured children seen at universal local public health units.

The Advisory Committee on Immunization Practices (ACIP) voted to add MENHIBRIX® to the VFC Program in February 2013; the ACIP stated their intention to focus the routine use of this combination vaccine among infants at increased risk for meningococcal disease. Infants at increased risk for meningococcal disease should be vaccinated with a 4-dose series of Hib-MenCY-TT at 2, 4, 6, and 12 – 15 months of age.

- Infants at high risk for meningococcal disease include: persistent complement pathway deficiencies, anatomic or functional asplenia, or sickle cell disease.
- Additionally, Hib-MenCY-TT can be used in infants ages 6 weeks through 18 months who are in communities with serogroups C and Y meningococcal disease outbreaks.
- Hib-MenCY-TT is not adequate for infants traveling to the Hajj or the "meningitis belt" of sub-Saharan Africa (a quadrivalent meningococcal vaccine that contains serogroups A and W135 is required for those infants).

If an infant at increased risk for meningococcal disease is behind on his or her Hib vaccine doses, Hib-MenCY-TT may be used following the same catch-up schedule used for Hib vaccine. However, if the first dose of Hib-MenCY-TT is given at or after 12 months of age, 2 doses should be given at least 8 weeks apart. For infants at increased risk for meningococcal disease who have received or are going to receive a different Hib vaccine product, ACIP recommends a 2-dose series of meningococcal conjugate vaccine (MCV4).

Hib-MenCY-TT may be co-administered with other routine infant vaccinations Hib-MenCY-TT should not be co-administered with other Hib-containing vaccines. Complete ACIP recommendations for Hib-MenCY-TT can be found at [www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a3.htm?s_cid=mm6203a3_w](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a3.htm?s_cid=mm6203a3_w).

An updated North Dakota Vaccine Coverage Table is available at [www.ndhealth.gov/immunize](http://www.ndhealth.gov/immunize).

If you have any questions or concerns, please contact the NDDoH Immunization Program at 701.328.3386 or toll-free at 800.472.2180.